Seaport Therapeutics raises 255 million in upsized IPO
The Boston-based biotech firm sold 14.16 million shares at 18 dollars each to develop neuropsychiatric therapies. It will list on Nasdaq under the ticker SPTX.
Xurve View
Insights:
Xurve View
Seaport Therapeutics raised $255M in an upsized IPO in the United States, selling 14.16M shares at $18 each. The offering exceeded the initial target of $212.4M. Previously, Boston-based Seaport had planned to raise up to $212.4 million by offering 11.8 million shares priced between $16 and $18 each. The clinical-stage biotech firm is developing oral therapies for neuropsychiatric disorders.
